SNNAQ (Sienna Biopharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2019)


What is Sienna Biopharmaceuticals LT-Debt-to-Total-Asset?

Sienna Biopharmaceuticals SNNAQ -99.00% LT-Debt-to-Total-Asset is 0.00 as of Sep. 2019.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sienna Biopharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2019 was 0.00.

Sienna Biopharmaceuticals's long-term debt to total assets ratio declined from Sep. 2018 (0.24) to Sep. 2019 (0.00). It may suggest that Sienna Biopharmaceuticals is progressively becoming less dependent on debt to grow their business.

Sienna Biopharmaceuticals  (OTCPK:SNNAQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sienna Biopharmaceuticals LT-Debt-to-Total-Asset Related Terms

Sienna Biopharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sienna Biopharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sienna Biopharmaceuticals LT-Debt-to-Total-Asset Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
LT-Debt-to-Total-Asset
0.00 0.00 0.00 0.28

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.28 0.26 0.28 0.00

Sienna Biopharmaceuticals LT-Debt-to-Total-Asset Calculation

Sienna Biopharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )/Total Assets (A: Dec. 2018 )
=30.125/107.306
=

Sienna Biopharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (Q: Sep. 2019 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2019 )/Total Assets (Q: Sep. 2019 )
=0/43.492
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Sienna Biopharmaceuticals (SNNAQ) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2019. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sienna Biopharmaceuticals and its competitors.
Is Sienna Biopharmaceuticals' LT-Debt-to-Total-Asset too high?
Sienna Biopharmaceuticals' current LT-Debt-to-Total-Asset is 0.00.
How does Sienna Biopharmaceuticals' LT-Debt-to-Total-Asset compare to GTHR and PPCB?
Sienna Biopharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sienna Biopharmaceuticals and its competitors. Sienna Biopharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sienna Biopharmaceuticals stock overvalued right now?
Sienna Biopharmaceuticals (SNNAQ) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sienna Biopharmaceuticals (SNNAQ), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sienna Biopharmaceuticals Business Description

Address 30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.